Healthcare / Diagnostics & ResearchKOSDAQ
$9620.00
-190.00 (-1.94%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 20%
FCF escenarios
weak_data · normalized FCF $-2.1B · quality 52.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
26/100
D
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$157.0B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-3.9%
↓Gross Margin
21.1%
↓Debt/Equity
0.01
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-28.2%
FCF CAGR
—
FCF margin
-6.9%
FCF / Net income
1.07x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $25.59B · net income $-1.64B · FCF $-1.76B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $25.59B | $25.59B | $25.04B | $30.79B | $69.01B |
| Net Income | $-1.64B | $-1.64B | $-2.84B | $645.9M | $13.16B |
| EBITDA | $-451.0M | $-451.0M | $-700.4M | $993.3M | $17.04B |
| EPS | -141.00 | -141.00 | -252.00 | 63.00 | 325.75 |
| Gross Margin | 21.1% | 21.1% | 20.1% | 26.7% | 38.6% |
| Operating Margin | -8.6% | -8.6% | -11.7% | -4.3% | 22.8% |
| Net Margin | -6.4% | -6.4% | -11.3% | 2.1% | 19.1% |
| Balance Sheet | |||||
| Debt/Equity | 0.01 | 0.01 | 0.01 | 0.01 | 0.02 |
| Current Ratio | 6.39 | 6.39 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-1.76B | $-1.76B | $-2.08B | $-3.53B | $23.26B |
| Returns | |||||
| ROE | -3.9% | -3.9% | -8.3% | 1.7% | 38.9% |
| Valuation | |||||
| P/E | — | — | — | 85.87 | 20.18 |
| EV/EBITDA | — | — | — | 20.77 | 15.53 |
| P/B | 2.65 | 2.65 | 0.90 | 1.46 | 7.85 |
| Growth & Yield | |||||
| Revenue Growth | 2.2% | 2.2% | -18.7% | -55.4% | — |
| EPS Growth | 44.0% | 44.0% | -500.0% | -80.7% | — |
| Dividend Yield | 1.0% | 1.0% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+203.5%
Start / end P/E
n/dx → n/dx
EPS bridge
-252.00 → -141.00
Residual
+202.5%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.